Chengdu YUNKE Pharmaceutical Co

Chengdu, China

Chengdu YUNKE Pharmaceutical Co

Chengdu, China
Time filter
Source Type

Wang Y.,University of Sichuan | Wang Y.,Sichuan Testing Center for Biomaterials and Medical Devices | Wang H.,Chengdu YUNKE Pharmaceutical Co. | Liang J.,University of Sichuan | Liang J.,Sichuan Testing Center for Biomaterials and Medical Devices
Lizi Jiaohuan Yu Xifu/Ion Exchange and Adsorption | Year: 2016

The advance of the preparation methods of polymer micro-spheres and nano-spheres were reviewed. The technical characteristics and main problems of the preparation for polymer microspheres with suspension polymerization, emulsion polymerization, dispersion polymerization, seed polymerization and microfluidic polymerization were introduced, as well as the recent progress in recent years. © 2016, Editorial Office, Ion Exchange and Adsorption. All right reserved.

Deng Q.,Chengdu YUNKE Pharmaceutical Co | Deng Q.,Chengdu Radiopharmaceutical Engineering Technology Research Center | Yin B.,Chengdu YUNKE Pharmaceutical Co | Yin B.,Chengdu Radiopharmaceutical Engineering Technology Research Center | And 4 more authors.
Hedongli Gongcheng/Nuclear Power Engineering | Year: 2014

The adsorption capacity for Sr and Y with Polyantimonic Acid (PAA) in 0.1 mol/L nitric acid solution was 16.25 mg/mL and 42.1 μg/g respectively. Sr and Y can't be separated with nitric acid solution of different concentration. More than 72% of Y can be eluted with 100 mL 0.02 mol/L EDTA as elution, but PAA was unstable in EDTA solution. 86.2% of Y can be desorbed with 20 mL 0.12 mol/L DTPA at the temperature is 80°C. The results indicated that PAA may be used for 90Y generator preparation, but system of generator should be rational designed to meet requires of 90Y generator.

Li M.,Chengdu Yunke Pharmaceutical Co.
Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi | Year: 2012

To provide a support to the clinical application of alendronate (Alen) on cytology, we studied the effects of Alen on the function of osteoblasts. In this experiment, we observed the influence of MG63 cell line co-incubation with Alen at concentrations of 1 x 10(-9) mol/L, 1 x 10(-7) mol/L or 1 x 10(-5) mol/L on the osteoblastic function (proliferation, cell morphology, alkali phosphatase (ALP) activity, expression of type I collagen and effect of calcium deposition). The proliferation, cell morphology, ALP activity and type I collagen synthesis of MG63 were not affected by Alen at concentration of 1 x 10(-9) mol/L and 1 x 10(-7) mol/L, but the ALP activity as well as type I collagen production were promoted at higher concentration (1 x 10(-5) mol/L). The calcium deposition of MG63 could be increased at the lower concentration (1 x 10(-9) mol/L), while it was inhibited at the higher concentration. In conclusion, Alen at low concentration can promote the mineralization ability of osteoblasts to a certain extent, and this benefits the bone formation.

Deng Q.-M.,Chengdu Yunke Pharmaceutical Co. | Cheng Z.-Y.,Chengdu Yunke Pharmaceutical Co. | Li M.-L.,Chengdu Yunke Pharmaceutical Co.
Hedongli Gongcheng/Nuclear Power Engineering | Year: 2011

Alumina (Al 2O 3) can be used for the extraction of MoO 4 2- and IO 3 - from UO 2(NO 3) 2 solution. IO 3 - can be reduced to I - by using Sodium sulphite, then MoO 4 2- and IO 3 - can be separated with Al 2O 3 for the unadsorption of I - on Al 2O 3. The total recovery yield of Mo and I is 78.3% ± 7.00% and 87.9% ± 5.48% respectively, after MoO 4 2- and IO 3 - in UO 2(NO 3) 2 solution were separated with two Al 2O 3 columns, and Mo in iodide products solution and I in molybdenic products solution meet the requirements. The results indicate that Al 2O 3 can be used for 99Mo and 131I separation from the fuel of Medical Isotope Production Reactor.

Chengdu Yunke Pharmaceutical Co. | Date: 2013-09-11

The present invention relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound provided in this present invention exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higer activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration schedule for the diphosphonate compound of the present invention is provided.

Loading Chengdu YUNKE Pharmaceutical Co collaborators
Loading Chengdu YUNKE Pharmaceutical Co collaborators